Thursday, December 04, 2014

Does the new Pneumonia vaccine PCV 13 - Prevenar, reduce rates of hospital admission due to pneumonia? Results from US data

The 7-valent pneumococcal conjugate vaccine (PCV7) was added to the U.S. infant immunization schedule in the year 2000. By 2009, PCV7 introduction was associated with a 43% decline in all-cause pneumonia among U.S. children aged <2 style="font-size: 0.85em; line-height: 0;" sup="" years.="">[1]
 In 2010, a new 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the infant immunization schedule, expanding protection from seven to 13 pneumococcal serotypes. To examine changes in all-cause pneumonia hospitalizations among children aged <2 1998="" after="" analyzed.="" data="" discharge="" for="" hospital="" nbsp="" p="" pcv13="" switch="" tennessee="" the="" to="" were="" years="">
By 2012, all-cause pneumonia hospitalizations in children aged <2 1="" 2012="" 27="" 4.1="" 72="" a="" additional="" an="" b="" be="" before="" decline="" declined="" estimated="" from="" had="" historically="" hospitalizations="" in="" introduction.="" low="" nbsp="" pcv7="" per="" pneumonia="" population="" rate="" relative="" represents="" that="" the="" to="" were="" years.="" years="">
Tennessee children aged <2 1="" 2011="" 2012="" a="" about="" and="" annually="" appropriate="" attest="" before="" causes="" children.="" conjugate="" current="" data="" decline="" experienced="" fewer="" hospitalizations="" impact="" in="" likely="" major="" management="" observed="" of="" on="" p="" pcv="" pneumococcal="" pneumonia="" powerful="" program="" reassessment="" represents="" should="" stimulate="" tennessee="" than="" the="" these="" to="" trend="" use.="" vaccine="" which="" years="">
Comment: While the Pneumonia vaccine has been introduced relatively later in India, and still faces a lot of resistance due to its high price (almost 4000 INR ~ 70 USD), this is good evidence that shows that it really reduces the risk of Invasive Pneumonia in the children. Data from India would be better, but is unsurprisingly unavailable.

No comments: